PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links


Article published in Urologia Polska 2000/53/2.

authors

R. Waidelich, Tomasz Z±bkowski, R. Baumgartner, H. Stepp, A. Hofstetter, M. Kriegmair
Department of Urology, University of Munich, Munich, Germany
The Head of Department of Urology Prof. Dr. A. G. Hofstetter
Urology Clinical, Military Medical Academy, Warsaw, Poland
The Head of Department of Urology Prof. Dr. B. Stawarz

keywords

bladder ? transitional cell carcinoma ? 5-ALA ? photodynamic therapy

references

  1. [1] Kriegmair, M, Waidelich, R, Lumper W, Ehsan, A, Baumgartner, R,
  2. Hofstetter, A.: Integral photodynamic treatment of refractory superficial bladder
  3. cancer. J. Urol. 1995,154,1339-1341.
  4. [2] Nseyo, U. O., Shumaker, B., Klein, E.A., Sutherland, K.: Photodynamic
  5. therapy using porfimer sodium as an alternative to cystectomy in patients with
  6. refractory transitional cell carcinoma in situ of the bladder. J. Urol. 1998,160,39-42.
  7. [3] Dougherty, T. J., Cooper, M. T., Mang, T. S.: Cutaneous phototoxic occur-
  8. rences in patients receiving photofrin. Lasers. Surg. Med. 1990,10, 485-488.
  9. [4] D'Hallewin, M. A., Baert, L.: Long-term results of whole bladder photodyna-
  10. mic therapy for carcinoma in situ of the bladder. Urology 1995, 45, 763-767.
  11. [5] Kennedy, J. C, Pottier, R. H.: Endogenous protoporphyrin IX, a clinically
  12. useful photosensitizer for photodynamic therapy. J. Photochem. Photobiol. B.,
  13. Biol. 1992,14, 275-292.
  14. [6] Kriegmair, M., Baumgartner, R., Knuchel, R., Stepp, I., Hofstadter,
  15. R, Hofstetter, A.: Detection of early bladder cancer by 5-aminolevulinic acid
  16. induced porphyrin fluorescence. J. Urol. 1996,155,105-108.
  17. [7] Steinbach, P., Kriegmair, M., Baumgartner, R., Hofstadter, F., Knuchel,
  18. R.: Intravesical instillation of 5-aminolevulinic acid. The fluorescence metabolite is
  19. limited to urothelial cells. Urology 1994, 44, 676-681.
  20. [8] Kriegmair, M., Baumgartner, R., Lumper, W., Waidelich, R., Hofstetter,
  21. A.: Early clinical experience with 5-aminolevulinic acid for the photodynamic the-
  22. rapy of superficial bladder cancer. Br. J. Urol. 1996, 77, 667-671.
  23. [9] Waidelich, R., Hofsterr, A., Stepp, H., Baumgartner, R., Weninger, E.,
  24. Kriegmair, M.: Early clinical experience with 5-aminolevulinic acid for the pho-
  25. todynamic therapy of upper tract urothelial tumors. J. Urol. 1998,159, 401-404.
  26. [10] Van Gemert, M. J. C, Cheong, W. F. , Welch, A. J., Star, W. M.: Light
  27. delivery for whole-bladder photodynamic therapy. Las in Med. Scien. 1987,
  28. 2, 273-284.
  29. [11] Hudson, M. A.: When intravesical measures fail. Urol. Clin. North. Amer. 1992,
  30. 19, 601-606.
  31. [12] Studer, U. E, Casanova, G., Kraft, R., Zingg, E. J.: Percutaneous bacillus
  32. Calmette Guerin perfusion of the upper urinary tract for carcinoma in situ. J. Urol.
  33. 1989,142, 975-978.
  34. [13] De Kock, M. L., Breytenbach, I. H.: Local excision and topical thiotepa in the
  35. treatment of transitional cell carcinoma of the renal pelvis, a case report. J. Urol.
  36. 1986,135, 566-569.
  37. [14] Weston, P. M., Greenland, J. E., Wallace, D. M.: Role of topical mitomycin
  38. C in upper urinary tract transitional cell carcinoma. Br. J. Urol. 1993, 71,624-626.